RASD2 and thyroid gland carcinoma: Through integrated analysis of published datasets, coupled with extensive cellular studies across multiple thyroid cancer cell lines, we demonstrated consistent RASD2 upregulation in both primary thyroid cancer tissues and malignant cell lines compared to their normal counterparts.